New Lower MoPath Prices Threaten Labs and Patient Access to Valuable Tests

The laboratory industry lobbied hard and successfully for placement of the new molecular pathology codes on the CLFS. The arguments were compelling. In hindsight, based on the pricing we have seen this week we have to ask ourselves if we may not have been better off with what the RUC proposed for the 77 codes that they priced. Laboratories may do well to look again at those prices and include them in their cost arguments to the contractors. The RUC analysis  is an accepted one and could lend credibility, along with factors such as the cost of things like kits and reagents, to a laboratory argument that the new prices will not allow them to continue to have viable businesses, thus reducing choice and access to these valuable tests.

Follow publications of pricing on the XiFin website